Role of clopidogrel in managing atherothrombotic cardiovascular disease

Area of Science:

• Cardiology
• Pharmacology
• Vascular Medicine

Background:

• Aspirin is the primary antiplatelet agent for vascular event prevention.
• Thienopyridines like clopidogrel offer alternatives for aspirin-intolerant patients, with clopidogrel showing better tolerability than ticlopidine.

Purpose of the Study:

• To evaluate the efficacy and safety of dual antiplatelet therapy (clopidogrel and aspirin) compared to aspirin alone.
• To assess the benefit-risk profile of dual therapy in different patient risk groups.

Main Methods:

• Review of evidence from randomized clinical trials comparing dual therapy with aspirin monotherapy.
• Analysis of benefit-risk profiles in high-risk (acute coronary syndromes, post-stenting) and low-risk (stable cardiovascular disease) populations.

Main Results:

• Dual therapy with clopidogrel and aspirin is modestly but significantly more effective than aspirin alone in preventing serious vascular events.
• Dual therapy shows a favorable benefit-risk profile in high-risk patients, particularly in acute coronary syndromes and after stenting.
• In low-risk patients with stable cardiovascular disease, the bleeding risk of dual therapy may exceed its benefits.

Conclusions:

• Dual antiplatelet therapy with clopidogrel and aspirin is a valuable strategy for high-risk patients but requires careful consideration of bleeding risks in low-risk populations.
• Further research is needed to clarify optimal treatment duration, dosing, use with other agents, and understanding of clopidogrel resistance.